Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond ICHD-3 criteria: Diagnostic challenges in headache in pediatric age.

Cephalalgia : an international journal of headache·2026

Same author

Unseen struggles: a narrative review of psychosocial and family outcomes following pediatric stroke.

Frontiers in psychology·2026

Same author

Sex-specific orchestration of morphometric similarity networks in children and adolescents with migraine.

Cephalalgia : an international journal of headache·2026

Same author

Migraine in pediatric population: the role of biochemical markers.

The journal of headache and pain·2026

Same author

Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Fremanezumab in Children and Adolescents with Migraine.

European journal of drug metabolism and pharmacokinetics·2026

Same author

Spontaneous closure of an atraumatic cervical spinal arteriovenous fistula in a pediatric patient.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026

Search research articles

Related Experiment Video

Updated: Nov 20, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

Fingolimod in pediatric multiple sclerosis: three case reports.

Michela Ada Noris Ferilli¹, Laura Papetti¹, Massimiliano Valeriani^2,3

¹Neurology Ward Unit, Bambino Gesù Children's Hospital, Piazza di Sant'Onofrio, 4, 00165, Rome, Italy.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

|January 23, 2021

Summary

Fingolimod offers a safe and effective treatment option for pediatric-onset multiple sclerosis (POMS), whether used as a first-line therapy for severe cases or as an escalated treatment, showing no disease progression in patients over one year.

Keywords:

Fingolimod First-choice therapy Multiple sclerosis Pediatric patients

More Related Videos

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

Related Experiment Videos

Last Updated: Nov 20, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

Area of Science:

Neurology
Immunology
Pediatrics

Background:

Pediatric-onset multiple sclerosis (POMS) treatment often mirrors adult protocols, despite distinct clinical courses.
Standard first-line POMS therapies include interferon β-1a or glatiramer acetate.
Natalizumab and fingolimod are typically second-line options, except in severe cases.

Observation:

This study examines three pediatric multiple sclerosis cases utilizing fingolimod.
Two cases involved escalation to fingolimod for disease progression in adolescent females.
One case used fingolimod as initial therapy for a 12-year-old male with severe POMS.

Findings:

Fingolimod demonstrated efficacy in both escalated and first-line treatment scenarios for POMS.
No disease progression was observed in any patient within one year of fingolimod initiation.
No adverse events were reported during the observation period.

Implications:

Fingolimod represents a viable therapeutic option within the POMS treatment algorithm.
Its use can be tailored based on disease severity and progression.
Further research into long-term outcomes and safety in POMS is warranted.